Myro Therapeutics
Harnessing the restorative potential of novel CNS therapeutics
- Headquarters
- Medford, Massachusetts
- Employees
- 1–10
- Business Model
- B2B
- Website
- myrotx.com
About
Myrobalan Therapeutics (formerly Myro Therapeutics) is a pre-clinical CNS biotech company developing first-in-class and best-in-class oral small molecule therapies for neurodegenerative and demyelinating disorders including multiple sclerosis, Alzheimer's disease, ALS, and Parkinson's disease. Founded on groundbreaking research from Harvard and MIT scientific co-founders, the company targets specialized CNS cell types—microglia and oligodendrocytes—to promote remyelination and reduce neuroinflammation. The company is supported by grants from the National Multiple Sclerosis Society and the ALS Association and completed a $24 million Series A financing in January 2024.
Summary
Myro Therapeutics is a Biotech company based in Medford, United States.
Tech & App Stack
2 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company